Manu Jain

  • 2658 Citations
1992 …2021
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My primary research interest is in lung repair after acute injury with a focus on TGF-beta mediated signaling. We have identified mitochondrial generated reactive oxygen species as important in TGF-bête mediated gene expression and are working to identify novel therapeutic targets in this pathway. We are also interested in modulating the ubiquitin-proteosomal pathway as a therapeutic target for tissue fibrosis. I have a clinical translational interest in Cystic Fibrosis. I am the site co-PI for the CF Foundation sponsored clinical trial network, The Therapeutic Development Network. I am also interested in the CF outcomes, especially related to chronic infection with Pseudomonas aeruginosa.

Certifications and Licenses

Pulmonary Disease
Internal Medicine
Critical Care Medicine

Training Experience

1990Internship, University of Chicago Pritzker School of Medicine
1992Residency, Univ. of Chicago Hospital
1996Fellowship, University of Chicago

Education/Academic qualification

MD, University of Chicago

… → 1989


  • Critical Care
  • Cystic Fibrosis
  • Fibrosis
  • Lungs / Breathing Problems
  • TGF-beta

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 16 Similar Profiles
Cystic Fibrosis Medicine & Life Sciences
Lung Medicine & Life Sciences
Adult Respiratory Distress Syndrome Medicine & Life Sciences
Acute Lung Injury Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Pulmonary Fibrosis Medicine & Life Sciences
Systemic Scleroderma Medicine & Life Sciences
Pseudomonas aeruginosa Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2002 2021

Research Output 1992 2018

Graft vs Host Disease
Multiple Myeloma

Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement

Heltshe, S. L., Rowe, S. M., Skalland, M., Baines, A. & Jain, M., Jun 1 2018, In : American Journal of Respiratory and Critical Care Medicine. 197, 11, p. 1483-1486 4 p.

Research output: Contribution to journalLetter

Cystic Fibrosis
1 Citations

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR

VX14-809-106 Investigator Group, Mar 1 2018, In : Journal of Cystic Fibrosis. 17, 2, p. 228-235 8 p.

Research output: Contribution to journalArticle

Cystic Fibrosis
Lung Diseases
Forced Expiratory Volume
ivacaftor drug combination lumacaftor

Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis

Soberanes, S., Misharin, A. V., Jairaman, A., Morales-Nebreda, L., McQuattie-Pimentel, A. C., Cho, T., Hamanaka, R. B., Meliton, A. Y., Reyfman, P. A., Walter, J. M., Chen, C-I., Chi, M., Chiu, S., Gonzalez-Gonzalez, F. J., Antalek, M., Abdala-Valencia, H., Chiarella, S. E., Sun, K. A., Woods, P. S., Ghio, A. J. & 12 othersJain, M., Perlman, H., Ridge, K. M., Morimoto, R. I., Sznajder, J. I., Balch, W. E., Bhorade, S. M., Bharat, A., Prakriya, M., Chandel, N. S., Mutlu, G. M. & Budinger, G. R. S., Oct 11 2018, In : Cell Metabolism.

Research output: Contribution to journalArticle

Air Pollution
Electron Transport
Particulate Matter
Alveolar Macrophages
1 Citations

Tezacaftor for the treatment of cystic fibrosis

Sala, M. A. & Jain, M., Sep 2 2018, In : Expert Review of Respiratory Medicine. 12, 9, p. 725-732 8 p.

Research output: Contribution to journalArticle

Cystic Fibrosis
Phase III Clinical Trials
Drug Combinations
Drug-Related Side Effects and Adverse Reactions